<DOC>
	<DOC>NCT00860496</DOC>
	<brief_summary>A new immunosuppressive drug, based on the inhibition of important enzymes in the immune system, called JAK, is being developed by Pfizer to prevent transplant rejection. Since many treatments for transplant rejection may be administered together, this research study will analyze the effects of common transplant rejection therapies, Tacrolimus and Cyclosporine, on the JAK inhibitor, CP-690,550.</brief_summary>
	<brief_title>A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy males between 21 and 55 years, inclusive. Healthy females of nonchildbearing potential between 21 and 55 years, inclusive. Total body weight greater than 132 pounds. Evidence or history of clinically significant disease Females of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Immunosuppression, JAK3 inhibitor, calcineurin inhibitors, tacrolimus, cyclosporine, pharmacokinetics, safety, tolerability</keyword>
</DOC>